II期临床-话题@MedSci

#II期临床#

478篇内容 | 2565人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1524867, encodeId=49c1152486e9d, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=ADAURA III期临床研究结果公布：奥希替尼治疗中枢神经系统转移可改善无病生存期, objectType=article, longId=201090, objectId=24af2010905f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24af2010905f, replyNumber=0, likeNumber=48, createdTime=2020-09-24, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24af2010905f, moduleTitle=ADAURA III期临床研究结果公布：奥希替尼治疗中枢神经系统转移可改善无病生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24af2010905f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524866, encodeId=c6fe1524866d1, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=NEJM：贝利木单抗治疗活动性狼疮性肾炎III期临床获得成功, objectType=article, longId=200854, objectId=2372200854b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2372200854b6, replyNumber=0, likeNumber=48, createdTime=2020-09-19, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2372200854b6, moduleTitle=NEJM：贝利木单抗治疗活动性狼疮性肾炎III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2372200854b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524865, encodeId=4c191524865e7, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Lancet Infect Dis：II价艰难梭菌疫苗III期临床研究失败, objectType=article, longId=200768, objectId=614b200e686d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=614b200e686d, replyNumber=0, likeNumber=78, createdTime=2020-09-18, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=614b200e686d, moduleTitle=Lancet Infect Dis：II价艰难梭菌疫苗III期临床研究失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=614b200e686d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524864, encodeId=19a5152486402, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=挑战25年来的共识！阿尔兹海默症疫苗即将开展III期临床，这家公司剑指tau蛋白阿喀琉斯之踵, objectType=article, longId=200686, objectId=c99d2006862e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c99d2006862e, replyNumber=0, likeNumber=58, createdTime=2020-09-16, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c99d2006862e, moduleTitle=挑战25年来的共识！阿尔兹海默症疫苗即将开展III期临床，这家公司剑指tau蛋白阿喀琉斯之踵, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c99d2006862e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524862, encodeId=e0de152486234, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Lancet：Vosoritide治疗儿童软骨发育不良III期临床获得成功, objectType=article, longId=200296, objectId=bd47200296fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd47200296fe, replyNumber=0, likeNumber=64, createdTime=2020-09-07, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd47200296fe, moduleTitle=Lancet：Vosoritide治疗儿童软骨发育不良III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bd47200296fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524863, encodeId=f99c152486315, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=NEJM：NVX-CoV2373新冠肺炎疫苗I-II期临床数据喜人, objectType=article, longId=200219, objectId=a20d20021917, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a20d20021917, replyNumber=0, likeNumber=12, createdTime=2020-09-05, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a20d20021917, moduleTitle=NEJM：NVX-CoV2373新冠肺炎疫苗I-II期临床数据喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a20d20021917)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524861, encodeId=6d4815248617e, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=NEJM：Tepotinib治疗MET外显子14跳跃突变非小细胞肺癌II期临床效果显著, objectType=article, longId=200217, objectId=5dcd20021e20, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5dcd20021e20, replyNumber=0, likeNumber=50, createdTime=2020-09-05, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5dcd20021e20, moduleTitle=NEJM：Tepotinib治疗MET外显子14跳跃突变非小细胞肺癌II期临床效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5dcd20021e20)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524860, encodeId=0f7a152486014, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=阿斯利康新冠疫苗计划在全球招募5万名志愿者，美国III期临床开启, objectType=article, longId=200167, objectId=7b7b20016e1e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b7b20016e1e, replyNumber=0, likeNumber=59, createdTime=2020-09-04, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b7b20016e1e, moduleTitle=阿斯利康新冠疫苗计划在全球招募5万名志愿者，美国III期临床开启, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b7b20016e1e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524859, encodeId=497515248591f, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Xerava（eravacycline）治疗复杂腹腔内感染：即将开展中国III期临床试验, objectType=article, longId=200046, objectId=dd8a2000461b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd8a2000461b, replyNumber=0, likeNumber=70, createdTime=2020-08-31, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd8a2000461b, moduleTitle=Xerava（eravacycline）治疗复杂腹腔内感染：即将开展中国III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd8a2000461b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524858, encodeId=04291524858f2, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=SLEEP 2020：DAYVIGO（lemborexant）治疗成年失眠，III期临床确认了其有效性和安全性, objectType=article, longId=200038, objectId=5362200038e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5362200038e5, replyNumber=0, likeNumber=82, createdTime=2020-08-31, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5362200038e5, moduleTitle=SLEEP 2020：DAYVIGO（lemborexant）治疗成年失眠，III期临床确认了其有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5362200038e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524857, encodeId=6b8a152485eb0, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=SLEEP 2020：失眠患者的福音，Daridorexant的III期临床取得积极进展, objectType=article, longId=200035, objectId=4a2d20003511, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a2d20003511, replyNumber=0, likeNumber=90, createdTime=2020-08-31, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a2d20003511, moduleTitle=SLEEP 2020：失眠患者的福音，Daridorexant的III期临床取得积极进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a2d20003511)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524856, encodeId=7b63152485640, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=JAMA：灭活全病毒Covid-19疫苗I-II期临床获得成功, objectType=article, longId=199946, objectId=6817199946dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6817199946dd, replyNumber=0, likeNumber=104, createdTime=2020-08-28, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6817199946dd, moduleTitle=JAMA：灭活全病毒Covid-19疫苗I-II期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6817199946dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524855, encodeId=b1601524855e6, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=FDA和EMA批准OPT-302治疗湿性AMD的III期临床试验, objectType=article, longId=199865, objectId=756f199865ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=756f199865ac, replyNumber=0, likeNumber=60, createdTime=2020-08-25, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=756f199865ac, moduleTitle=FDA和EMA批准OPT-302治疗湿性AMD的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=756f199865ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524854, encodeId=3b2b1524854d6, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=NEJM：Venetoclax治疗急性髓性白血病（AML），III期临床取得正面结果, objectType=article, longId=199491, objectId=6d08199491a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d08199491a0, replyNumber=0, likeNumber=56, createdTime=2020-08-16, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d08199491a0, moduleTitle=NEJM：Venetoclax治疗急性髓性白血病（AML），III期临床取得正面结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d08199491a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524853, encodeId=cea915248531d, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=食管癌及胃食管连接部癌术后欧狄沃（纳武利尤单抗）辅助治疗III期临床研究CheckMate -577达到主要终点无病生存期, objectType=article, longId=199310, objectId=a5e8199310d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5e8199310d0, replyNumber=0, likeNumber=58, createdTime=2020-08-14, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5e8199310d0, moduleTitle=食管癌及胃食管连接部癌术后欧狄沃（纳武利尤单抗）辅助治疗III期临床研究CheckMate -577达到主要终点无病生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5e8199310d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524852, encodeId=8f6715248523f, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=MS1819联合PERT治疗胰腺功能不全的囊性纤维化：II期临床取得积极进展, objectType=article, longId=199301, objectId=8caa199301e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8caa199301e8, replyNumber=0, likeNumber=53, createdTime=2020-08-14, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8caa199301e8, moduleTitle=MS1819联合PERT治疗胰腺功能不全的囊性纤维化：II期临床取得积极进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8caa199301e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524851, encodeId=0ae8152485153, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=胃癌与食管癌一线治疗！欧狄沃（纳武利尤单抗）+化疗方案III期临床数据：显著提升总生存期与无进展生存期, objectType=article, longId=199268, objectId=b8ff199268d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8ff199268d0, replyNumber=0, likeNumber=68, createdTime=2020-08-13, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8ff199268d0, moduleTitle=胃癌与食管癌一线治疗！欧狄沃（纳武利尤单抗）+化疗方案III期临床数据：显著提升总生存期与无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8ff199268d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524850, encodeId=a2d5152485088, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=CheckMate-743是且**证明一线免疫治疗能够改善恶性胸膜间皮瘤患者生存获益的III期临床试验, objectType=article, longId=199161, objectId=739d19916169, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=739d19916169, replyNumber=0, likeNumber=51, createdTime=2020-08-12, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=739d19916169, moduleTitle=CheckMate-743是且**证明一线免疫治疗能够改善恶性胸膜间皮瘤患者生存获益的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=739d19916169)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524849, encodeId=5b44152484908, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=阿斯利康的IL-5受体单抗Fasenra：III期临床证实在嗜酸性哮喘中具有强大疗效, objectType=article, longId=198911, objectId=81e1198911ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81e1198911ce, replyNumber=0, likeNumber=62, createdTime=2020-08-08, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81e1198911ce, moduleTitle=阿斯利康的IL-5受体单抗Fasenra：III期临床证实在嗜酸性哮喘中具有强大疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=81e1198911ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524848, encodeId=b1a71524848b8, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=AAIC 2020：II期临床证实重组GM-CSF对阿尔茨海默氏症有治疗潜力, objectType=article, longId=198856, objectId=39521988569d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39521988569d, replyNumber=0, likeNumber=70, createdTime=2020-08-08, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39521988569d, moduleTitle=AAIC 2020：II期临床证实重组GM-CSF对阿尔茨海默氏症有治疗潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39521988569d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

II期临床

2020-05-29

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

ADAURA III期临床研究结果公布：奥希替尼治疗中枢神经系统转移可改善无病生存期

2020-09-24

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

NEJM：贝利木单抗治疗活动性狼疮性肾炎III期临床获得成功

2020-09-19

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Lancet Infect Dis：II价艰难梭菌疫苗III期临床研究失败

2020-09-18

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

挑战25年来的共识！阿尔兹海默症疫苗即将开展III期临床，这家公司剑指tau蛋白阿喀琉斯之踵

2020-09-16

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Lancet：Vosoritide治疗儿童软骨发育不良III期临床获得成功

2020-09-07

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

NEJM：NVX-CoV2373新冠肺炎疫苗I-II期临床数据喜人

2020-09-05

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

NEJM：Tepotinib治疗MET外显子14跳跃突变非小细胞肺癌II期临床效果显著

2020-09-05

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

阿斯利康新冠疫苗计划在全球招募5万名志愿者，美国III期临床开启

2020-09-04

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Xerava（eravacycline）治疗复杂腹腔内感染：即将开展中国III期临床试验

2020-08-31

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

SLEEP 2020：DAYVIGO（lemborexant）治疗成年失眠，III期临床确认了其有效性和安全性

2020-08-31

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

SLEEP 2020：失眠患者的福音，Daridorexant的III期临床取得积极进展

2020-08-31

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

JAMA：灭活全病毒Covid-19疫苗I-II期临床获得成功

2020-08-28

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

FDA和EMA批准OPT-302治疗湿性AMD的III期临床试验

2020-08-25

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

NEJM：Venetoclax治疗急性髓性白血病（AML），III期临床取得正面结果

2020-08-16

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

食管癌及胃食管连接部癌术后欧狄沃（纳武利尤单抗）辅助治疗III期临床研究CheckMate -577达到主要终点无病生存期

2020-08-14

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

MS1819联合PERT治疗胰腺功能不全的囊性纤维化：II期临床取得积极进展

2020-08-14

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

胃癌与食管癌一线治疗！欧狄沃（纳武利尤单抗）+化疗方案III期临床数据：显著提升总生存期与无进展生存期

2020-08-13

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

CheckMate-743是且**证明一线免疫治疗能够改善恶性胸膜间皮瘤患者生存获益的III期临床试验

2020-08-12

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

阿斯利康的IL-5受体单抗Fasenra：III期临床证实在嗜酸性哮喘中具有强大疗效

2020-08-08

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

AAIC 2020：II期临床证实重组GM-CSF对阿尔茨海默氏症有治疗潜力

2020-08-08

科室
- - 订阅+
  - 更多科室
工具
服务